| Literature DB >> 32148488 |
Chen-Mei Zhao1, Xue-Li Cui1, Gang Wan2, Yu-Zhe Lu1, Yu-Qin Niu1, Cheng-Yu Su1, Shuo Cao1, Guan-Xiu Liang1, Hong-Wei Chen1, Jing Li1, Xia Lu1, Zhi-Yun Deng1, Xue-Hui Yu1, Wen-Xia Yang1, Jian-Hua Li1, Hua Fan1, Mao-Xia Yang1, Yan Fu1, Su-Ping Wei1, Zhi-Na He1, Xue-Lian Zhang3, Shen-Yuan Yuan3.
Abstract
OBJECTIVE: To investigate the effect of intensive management and achieving the target control more than 3 times on endpoint events during 9 consecutive years' annual assessment in type 2 diabetes (T2DM) patients in the Sanlitun Community Health Service Center in Beijing, including blood glucose, blood pressure, lipids profiles, and the joint target control.Entities:
Year: 2020 PMID: 32148488 PMCID: PMC7053495 DOI: 10.1155/2020/3646342
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Flow chart showing the number of study participants.
Comparison of clinical characteristics between the intensive group and the standard group at baseline (2008).
| Characteristics | Intensive group | Standard group | Statistical quantity |
|
|---|---|---|---|---|
| ( | ( | ( | ||
| Age (years) | 66.46 ± 8.47 | 65.55 ± 9.88 | 0.74 ( | 0.46 |
| Gender | ||||
| Male, | 39 | 39 | −0.00 ( | 1.00 |
| Female, | 74 | 72 | ||
| Duration of diabetes (years) | 9.0 (4.3, 13.0) | 5.5 (2.0, 11.0) | 1.49 ( | 0.14 |
| Smoker | ||||
| Yes | 11 | 7 | 0.49 ( | 0.49 |
| No | 102 | 104 | ||
| Body mass index (kg/m2) | 25.12 ± 3.31 | 25.32 ± 3.57 | −0.42 ( | 0.68 |
| Systolic blood pressure (mmHg) | 129.03 ± 13.49 | 127.34 ± 12.53 | 0.96 ( | 0.34 |
| Diastolic blood pressure (mmHg) | 76.59 ± 7.40 | 77.9 ± 6.43 | −1.40 ( | 0.16 |
| FPG (mmol/L) | 7.69 ± 2.46 | 8.18 ± 2.77 | −1.36 ( | 0.17 |
| HPG (mmol/L) | 9.19 ± 2.90 | 9.82 ± 3.22 | −1.30 ( | 0.20 |
| HbA1c (%) | 7.37 ± 1.28 | 7.78 ± 1.82 | −1.92 ( | 0.06 |
| LDL-cholesterol (mmol/l) | 2.79 ± 0.82 | 2.84 ± 0.91 | −0.45 ( | 0.65 |
| UAER ( | 6.25 (4.69, 12.96) | 6.78 (5.21, 14.17) | −1.05 ( | 0.29 |
N = number of individuals. Values are expressed as mean ± SD, median (Q1, Q3), or number (%). P values indicate statistical significance of the differences among the three groups. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; HPG, 2-hour postprandial blood glucose; HbA1c, hemoglobin A1c; UAER, urinary albumin excretion rate.
Comparison of clinical characteristics between the intensive group and the standard group at the end of follow-up (2017).
| Characteristic | Intensive group | Standard group | Statistical quantity |
|
|---|---|---|---|---|
| ( | ( | ( | ||
| Body mass index (kg/m2) | 24.93 ± 2.74 | 25.79 ± 3.70 | −1.68 ( | 0.09 |
| Systolic blood pressure (mmHg) | 126.95 ± 9.93 | 127.75 ± 11.30 | −0.49 ( | 0.62 |
| Diastolic blood pressure (mmHg) | 71.47 ± 7.90 | 71.04 ± 7.43 | 0.36 ( | 0.72 |
| FPG (mmol/L) | 7.25 ± 1.73 | 8.07 ± 2.13 | −2.78 ( | 0.01 |
| HPG (mmol/L) | 8.34 ± 1.52 | 10.03 ± 3.13 | −4.3 ( | 0.01 |
| HbA1c (%) | 6.87 ± 1.14 | 7.43 ± 1.39 | −2.81 ( | 0.01 |
| LDL-cholesterol (mmol/l) | 2.50 ± 1.03 | 2.89 ± 0.86 | −2.64 ( | 0.01 |
| UAER ( | 6.32 (0.37, 275.33) | 8.69 (2.08, 524.28) | −2.55 ( | 0.01 |
N = number of individuals. Values are expressed as mean ± SD, median (Q1, Q3), or number (%). P values indicate statistical significance of the differences among the three groups. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; HPG, 2-hour postprandial blood glucose; HbA1c, hemoglobin A1c; UAER, urinary albumin excretion rate.
The incidence of endpoint events between the two groups.
| End-point events | Intensive group | Standard group | Log-rank |
|
|---|---|---|---|---|
| ( | ( | |||
| All-cause death | 9 (7.96) | 14 (12.61) | 2.51 | 0.11 |
| Coronary heart disease | 11 (9.73) | 7 (6.31) | 0.43 | 0.51 |
| Cerebrovascular disease | 9 (7.64) | 11 (9.91) | 1.26 | 0.26 |
| Stenosis or occlusion of large arteries | 3 (2.65) | 7 (6.31) | 3.15 | 0.08 |
| Diabetic retinopathy | 1 (0.88) | 6 (5.41) | 5.89 | 0.02 |
| Diabetic nephropathy | 5 (4.42) | 13 (11.71) | 5.44 | 0.02 |
| Malignant tumor | 6 (5.31) | 9 (8.11) | 1.05 | 0.31 |
Figure 2Cumulative incidences of all-cause end-point events during the follow-up between the two groups.
Comparison of the endpoint events in patients who achieved the target control (HbA1c, blood pressure, LDL-C, and the joint target control) >3 times and <3 times.
| Clinical characteristics |
| All-cause death | Coronary heart disease | Cerebrovascular disease | Stenosis or occlusion of large arteries | Diabetic microvascular complications | Malignant tumor |
|---|---|---|---|---|---|---|---|
|
| |||||||
| ≥3 times | 150 | 9 (6.00) | 13 (8.67) | 14 (9.33) | 4 (2.67) | 18 (12.00) | 6 (4.00) |
| <3 times | 74 | 14 (18.92) | 5 (6.76) | 6 (8.11) | 6 (8.11) | 7 (9.46) | 9 (12.16) |
|
| 13.49 | 0.01 | 0.21 | 7.93 | 0.11 | 6.86 | |
|
| 0.00 | 0.92 | 0.65 | 0.01 | 0.75 | 0.01 | |
|
| |||||||
|
| |||||||
| ≥3 times | 144 | 10 (6.94) | 10 (6.94) | 9 (6.25) | 3 (2.08) | 13 (9.03) | 7 (4.86) |
| <3 times | 80 | 13 (16.25) | 8 (10.00) | 11 (13.75) | 7 (8.75) | 12 (15.00) | 8 (10.00) |
|
| 7.77 | 2.04 | 7.17 | 9.65 | 4.39 | 3.21 | |
|
| 0.01 | 0.15 | 0.01 | 0.00 | 0.04 | 0.07 | |
|
| |||||||
|
| |||||||
| ≥3 times | 104 | 7 (6.73) | 10 (9.62) | 8 (7.69) | 4 (3.85) | 10 (9.62) | 4 (3.85) |
| <3 times | 120 | 16 (13.33) | 8 (6.67) | 12 (10.00) | 6 (5.00) | 15 (12.50) | 11 (9.17) |
|
| 4.9 | 0.06 | 2.24 | 1.34 | 2.15 | 3.7 | |
|
| 0.03 | 0.81 | 0.13 | 0.25 | 0.14 | 0.06 | |
|
| |||||||
|
| |||||||
| ≥3 times | 61 | 1 (1.64) | 6 (9.84) | 0 (0.00) | 0 (0.00) | 3 (4.92) | 1 (1.64) |
| <3 times | 163 | 22 (13.50) | 12 (7.36) | 20 (12.27) | 10 (6.13) | 22 (13.50) | 14 (8.59) |
|
| 8.63 | 0 | 11.35 | 6.15 | 5.66 | 4.12 | |
|
| 0.00 | 0.96 | 0.00 | 0.01 | 0.02 | 0.04 | |